ReviewEndocrine2017
Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.
Review in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies.Scientific reports · 2019Pooled it
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Cardiac Resynchronization Therapy With Defibrillator for Acromegalic Cardiomyopathy With Left Bundle Branch Block.JACC. Case reports · 2026Article
- Consensus on acromegaly complications: an update.Pituitary · 2026Article
- Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study.Frontiers in endocrinology · 2026Article
- Anesthetic Management for Pituitary Tumor Resection in a Patient With Acromegalic Cardiomyopathy: A Case Report.Clinical case reports · 2025Article
- Acromegaly and Cardiovascular Disease: Associated Cardiovascular Risk Factors, Cardiovascular Prognosis, and Therapeutic Impact.Journal of clinical medicine · 2025Review
- Cardiac structure and function recovery in acromegaly after treatment: insights from cardiac magnetic resonance imaging.Frontiers in endocrinology · 2025Article
- Article
- An Overview of Cardiovascular Risk in Pituitary Disorders.Medicina (Kaunas, Lithuania) · 2024Review
- Three-Dimensional Speckle-Tracking Echocardiography-Derived Tricuspid Annular Properties in Acromegaly-Results from the MAGYAR-Path Study.Biomedicines · 2024Article
- Myocardial, Valvular, and Vascular Structural and Functional Properties in Acromegaly.Journal of clinical medicine · 2023Review
- Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis.Journal of the Endocrine Society · 2023Article
- Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish populationTurkish journal of medical sciences · 2021Article
- Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?Journal of endocrinological investigation · 2021Review
- Advances in Research on the Cardiovascular Complications of Acromegaly.Frontiers in oncology · 2021Review
- Diabetes mellitus deteriorates left ventricular deformation in acromegaly-analysis from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path study.Quantitative imaging in medicine and surgery · 2021Article
- Common Pitfalls in the Interpretation of Endocrine Tests.Frontiers in endocrinology · 2021Review
- Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center.Frontiers in endocrinology · 2021Article
- Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.Journal of diabetes and metabolic disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbidities related to the cardiovascular system are one of the most prevalent in patients with acromegaly, and contribute to an increased risk of morbidity and all-cause mortality. Specifically, hypertension, cardiomyopathy, heart valve disease, arrhythmias, atherosclerosis, coronary artery disease, and cardiac dysfunction may be frequent findings. Although the underlying physiopathology for each comorbidity may not be fully elucidated, uncontrolled growth hormone/insulin-like growth factor 1 excess, age, prolonged disease duration, and coexistence of other cardio-vascular risk factors are significant influencing variables. A simple diagnostic approach to screen for the presence of these comorbidities may allow prompt treatment and arrest the progression of cardiac abnormalities. In this article, we revise the most prevalent cardiovascular comorbidities and their pathophysiology in acromegalic patients, and we address some recommendations for their prompt diagnosis, management and treatment. Strengths and pitfalls of different diagnostic techniques that are currently being used and how different treatments can affect these complications will be further discussed.
Indexed as
Identifiers
28042644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.